Cytomx Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
151 Oyster Point Blvd Ste 400, South San...Phone Number
(650) 515-3185Website
www.cytomx.comRevenue
$35.5 MillionStock Symbol
CTMXIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
2
About Cytomx Therapeutics
CytomX Therapeutics is a NASDAQ-listed clinical-stage biopharmaceutical company dedicated to revolutionizing oncology treatments. The company utilizes its proprietary Probody® therapeutic platform to develop conditionally activated, masked biologic drugs. This technology is designed to localize drug activity specifically to the tumor microenvironment, thereby increasing efficacy against cancer while minimizing damage and toxicity to healthy tissues throughout the rest of the body. CytomX's robust pipeline includes Probody drug conjugates (ADCs) and T-cell engaging bispecific antibodies, targeting unmet needs in solid tumors and other cancers. The company operates on a hybrid business model, generating revenue through extensive R&D and milestone payments from major strategic partnerships with pharmaceutical leaders like Bristol Myers Squibb and Amgen.Explore more
Cytomx Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytomx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cytomx Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Cytomx Therapeutics
Earning: See what the market has to say on Cytomx Therapeutics recently announced quarterly report
Click to see if Cytomx Therapeutics had a recent Job posting/layoffs
Check out if Cytomx Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Cytomx Therapeutics has new funding data
Cytomx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Cytomx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Cytomx Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Cytomx Therapeutics
Compare insights from companies similar to Cytomx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cytomx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cytomx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cytomx Therapeutics.
Cytomx Therapeutics financials insights
Gather financial insights about Cytomx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$1.3M
2012
Series B
$41M
2015
Multiple Rounds
$182M
2018
Stock Offering
$116.9M
Cytomx Therapeutics Tech Stack
A closer look at the technologies used by Cytomx Therapeutics
See more technologies
Most Recent Scoops
Project
reported that the March 2026 Varseta-M expansion phase update showed no evidence of EpCAM-mediated toxicities, a very low incidence of hematologic toxicities, no interstitial lung disease.
Medical Research
Project
Cytomx Therapeutics has initiated a bevacizumab combination study for Varseta-M, with first data expected in the first half of 2027, as a foundational step toward advancing the drug into third-line colorectal cancer treatment with no anticipated overlapping toxicities between the two agents.
Medical Research, Pharmaceuticals
Project
presented an update from the Varseta-M expansion phase in March 2026, showing overall response rates of 20% to 32% across three dose levels (7.2, 8.6, and 10 mg/kg, with 20 patients enrolled at each) in a fourth-line or later colorectal cancer population, compared to an approximately 1% to 2% response rate for current standard of care, with a median progression-free survival of 7 months versus approximately 2 to 3 months for standard of care.
Medical Research, Clinical Operations
Project
Cytomx Therapeutics has announced plans to initiate chemotherapy combination studies for Varseta-M in the second half of the current year, with the ultimate goal of replacing irinotecan in the second-line FOLFIRI regimen given that Varseta-M employs the same topo I mechanism in a superior antibody drug conjugate format.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Cytomx Therapeutics News & Media
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Therapeutics, Inc. (CTMX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 9:20 AM EDTCompany ParticipantsSean McCarthy -...CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -CytomX Therapeutics to Present at Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June.CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. In this role, Dr. Gokhale will lead CytomX’s global regulatory strategy and oversee regulatory engagement to support the continued advancement of the Company’s PROBODY® pipeline through clinical development and toward
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytomx Therapeutics
Sign Up For FreeTo access detailed company insights
CytomX Therapeutics is a NASDAQ-listed clinical-stage biopharmaceutical company dedicated to revolutionizing oncology treatments. The company utilizes its proprietary Probody® therapeutic platform to develop conditionally activated, masked biologic drugs. This technology is designed to localize drug activity specifically to the tumor microenvironme... Read More
